Bruce Morimoto

Thursday 20th August 2026

Pannel Discussion: Beyond Transferrin Receptors Unlocking Safer & More Specific CNS Oligo Delivery for the Next Generation of BBB Shuttles

10:30 am

Reassessing the limitations of TfR1-mediated delivery including broad peripheral expression, systemic sink effects, tolerability concerns, and limited cell-type specificity and evaluating whether alternative receptors such as CD98, IGF1R, peptide ligands and LNP-enabled formats can deliver improved CNS selectivity
Examining emerging BBB access strategies, including receptor alternatives and physical modulation approaches such as antibody-mediated opening or focused ultrasound, while balancing enhanced penetration against the biological risks of barrier disruption

Friday 21st August 2026

Panel Discussion: Diversifying CNS Delivery of Oligos: Nanoparticles, AAV, Peptide Carriers, Physical & Non- Physical BBB Modulation

4:30 pm

Exploring LNP strategies for CNS delivery, discussing their capacity to encapsulate and protect oligonucleotides, enhance systemic stability, modulate biodistribution, and potentially enable controlled transport across or around the blood–brain barrier
Advancing peptide-mediated delivery approaches that utilize small targeting or cell-penetrating peptides to facilitate BBB traversal and intracellular uptake, evaluating their modularity, scalability, and potential advantages over antibody-based shuttle platforms
Evaluating physical BBB modulation techniques, including focused ultrasound and microbubble-assisted disruption, to transiently increase permeability and enable localized brain access, while critically assessing reversibility, safety margins, spatial precision, and translational feasibility

Friday 21st August 2026

Chair’s Opening Remarks

8:55 am

Friday 21st August 2026

Chair’s Closing Remarks & End of Conference

5:05 pm